oncotarget.9551

Relaxin R1/LGR7 Antibody (933344) [Alexa Fluor® 700] Summary

    Immunogen
    Chinese hamster ovary cell line CHO-derived recombinant human Relaxin R1
    Met1-Ser398
    Accession # Q9HBX9
    Specificity
    Detects human Relaxin R1 in direct ELISAs and detects human, mouse, and rat Relaxin R1 in Western blots.
    Isotype
    IgG1
    Clonality
    Monoclonal
    Host
    Mouse
    Innovators Reward
    Test in a species/application not listed above to receive a full credit towards a future purchase.

    Learn about the Innovators Reward

Applications/Dilutions

    Dilutions
        Flow Cytometry 0.25-1 ug/10^6 cells

Packaging, Storage & Formulations

    Storage
    Store the unopened product at 2 – 8 °C. Do not use past expiration date.
    Buffer
    Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Relaxin R1/LGR7 Antibody (933344) [Alexa Fluor® 700]

      leucine-rich repeat-containing G protein-coupled receptor 7
      Leucine-rich repeat-containing G-protein coupled receptor 7
      LGR7
      LGR7.1
      LGR7.10
      LGR7LGR7.2
      MGC138347
      MGC142177
      Relaxin family peptide receptor 1
      Relaxin R1
      relaxin receptor 1
      relaxin/insulin-like family peptide receptor 1
      RelaxinR1
      RXFP1
      RXFPR1

Background

Relaxin R1 (Relaxin Receptor 1), also known as RXFP1 (Relaxin Family Peptide Receptor 1) or LGR7 (Leucine‑rich G‑protein‑coupled Receptor 7) is a member of family C of the LGRs, and is one of four receptors for Relaxin family proteins. Relaxin R1 shows highest affinity for human Relaxins 1, 2 and 3, while RXFP2 binds Relaxin 2 and the related INSL3, and RXFP3 primarily binds Relaxin 3 (1, 2). The 757 amino acid (aa) human Relaxin R1 contains an N‑terminal 409 aa extracellular domain (ECD) with a calcium‑binding LDL R class A (LDLa) domain and 10 leucine‑rich repeats (LRR) with several N‑glycosylation sites. The C‑terminus contains 12 transmembrane domains within aa 410‑672. Human Relaxin R1 (aa 1‑398) shares 84, 86, 85, 85 and 91% aa sequence identity with mouse, rat, equine, bovine and porcine Relaxin R1, respectively. Isoforms of 724 and 709 aa lack aa 63‑96 and 300‑348, respectively, while isoforms of 176, 189, 191 and 337 aa diverge after aa 154, 179, 181 and 324, respectively (3, 4). These forms may dimerize with full‑length Relaxin R1 and reduce its expression on the cell surface (3, 4). Receptor activation and cAMP signaling depend on the LDLa domain, and Relaxin binding requires the LRR repeats, with a secondary binding site within transmembrane region exoloops (1, 2, 5). Of LGR family members, RXFP1 and RXFP2 are unique in that they are not internalized to down‑regulate signaling, and their LDLa domains allow transmission of both G‑protein‑dependent and ‑independent signals (1, 2, 6, 7). Engagement of Relaxin R1 by Relaxin (mainly Relaxin 2 in humans) supports female reproduction by promoting uterine angiogenesis, ovarian follicle ripening, and endometrial, cervical and nipple development (8‑10). In male reproduction, Relaxin R1 acts in the prostate to enhance sperm motility (11). It reduces fibrosis in the heart, skin, lungs, liver, kidney, and reproductive tissues by combating aberrant collagen buildup (12). In the vasculature, it mediates vasodilation and decreases blood pressure. Relaxin R1 is expressed on human leukocytes and promotes adhesion, migration, and osteoclast differentiation (13, 14). Additional effects on heart, lungs, kidney and brain are reported, some of which may be species‑specific (1).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

LDN193200

Related Post